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Thioredoxins are vital components of Plasmodium proteome and act as both reducing agents and protein
disulfidereductases.ThemalariaparasiteP.falciparumthioredoxin-2(PfTrx-2)ispartofthemulti-protein
complex embedded within the parasite parasitophorous vacuolar membrane (PVM) which purportedly
directsprotein secretion.Wehavecharacterized structuraland enzymaticfeaturesof PfTrx-2,and weshow
that PfTrx-2 adopts a canonical thioredoxin fold but with significant structural differences in its
N-terminus.Ourconfocal localizationdatasuggestdistinctPVMresidencyofPfTrx-2.Basedonthecrystal
structureofPfTrx-2, wescreenedandtestedsmallmoleculedrug-likelibrariesforcompoundswhichtarget
unique structural features of PfTrx-2. Disruption of PfTrx-2 interactions using specific inhibitors may
result in a dysfunctional parasite translocon that is rendered unable to secrete pathogenic proteins into
hosts. This approach therefore offers a new focus for anti-malarial drug development.
M
alariaisoneoftheworld’smostimportantinfectiousdiseasesandisresponsibleforenormousmortality
and morbidity
1. The unicellular parasite Plasmodium falciparum causes most aggressive form of this
disease, leading to severe malaria
1. Malaria parasites are constantly exposed to high fluxes of toxic
reactive oxygen species (ROS) and to counter this they have developed elaborate redox systems comprising of
thioredoxins, peroxoredoxins, glutathiones and superoxide dismutases amongst others
2. Maintenance of proper
redoxbalanceisthereforeclearlyvitalforerythrocyticstagesofPlasmodium,ashasbeendemonstratedbymalaria
protective effects of glucose-6-phosphate deficiency
3. A tight control on parasitic redox balance is alsoimportant
due to the different intra- and extracellular environments the parasite is exposed to. Oxidative stress is induced
within the parasite due to its high metabolic and replicative rates, due to the constant reliance on host hae-
moglobin digestion, and due to ROS produced by the host
2,4–6. Plasmodium apparently lacks some important
componentsofredoxsystemsviz.,catalaseandagenuineglutathioneperoxidase
5,7.Itwasrecentlyshownthatthe
parasite imports human peroxiredoxin-2 for peroxide detoxification
7–11. These unique features of Plasmodium
redox biology can provide valuable targets for development of specific anti-malarials.
Plasmodium falciparum contains three thioredoxins - Trx1, Trx2, Trx3 and two thioredoxin-like proteins
(Tlp1 and Tlp2)
5,12. Trx1 and Tlp1 are cytosolic, Trx3 is localized to the endoplasmic reticulum, while Tlp2 is
mitochondrial
13.Thioredoxin2(PfTrx-2fromhereon,MAL13P1.225),thefocusofthispresentwork,isa19 kDa
protein with an ER signal sequence. Significantly, PfTrx-2 was recently shown to be part of the so-called
translocon complex (PTEX) which is a parasite derived multi-protein machinery resident in parasite parasito-
phorous vacuolar membrane (PVM), responsible for protein secretion into host cells
14. Plasmodium parasite
remodels the red blood cells by exporting ,5% of its encoded genome (,300 proteins)
15–18. These exported
proteins are critical for parasite survival in host cells as they play important roles in nutrient uptake, immune
evasion and virulence associated functions of the parasite
19–22. Protein translocation is a complex process as it
involves crossing three membranes viz. endoplasmic reticulum, parasite plasma membrane and parasitophorous
vacuolar membrane. A hydrophobic signal sequence at the N-terminus of proteins is usually sufficient to target
themtotheERandsubsequentsecretion totheparasitophorousvacuole.However,howproteins aretransported
out of PVM to the host cytoplasm is not fully understood
23–25. The situation is even more complex for proteins
which are destined for red blood cell plasma membrane. A pentapeptide motif (RxLxE) named Plasmodium
exportelement(PEXEL)hasbeenidentifiedinproteinssecretedoutoftheparasitetothehostcell
14.PEXELmotif
ispresentinboththeproteinslackingasignalpeptidesequencesuchasPfEMP1familyaswellasthosehavingone
like Stevorfamily proteins
25.However,manyproteins lackingaPEXELmotifare alsosecreted out bythe parasite
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protease recognition site, cleaved by Plasmapsin V in the ER
26,27.I ti s
proposed that Plasmapsin V is more than a signal peptidase and it
targets PEXEL containing proteins to the PTEX translocon by chan-
neling the cleaved proteins to HSP101 chaperon
25–27. It is further
hypothesized that at the PTEX proteins are translocated through a
membrane pore formed by EXP2 protein
14,25. Other components of
PTEX include PTEX150, PTEX88 and HSP101 which together
enable secretion of parasite proteins that contain the PEXEL motif
14.
PfTrx-2 is a component of the PTEX, where it likely plays role of a
protein disulfide isomerase, assisting in protein unfolding before
translocation
14. A GFP fused PfTrx-2 was previously shown to be
mitochondrialocalized
28,butrecentstudieshaveshownittobePVM
localized as well as to an organelle of unknown identity, again based
on GFP-fusion constructs
13,14.
Here, wepresentcrystalstructure ofPlasmodium falciparumTrx2
(PfTrx-2) at 2.9 A ˚ resolution. Evidently, there is only partial conser-
vation in the PfTrx-2 active site residues, and PfTrx-2 structure
reveals several unique features when compared to its human
counterpart (HuTrx-2). We also show that disabling PfTrx-2 func-
tion by small molecule inhibitors is likely to block or reduce proces-
sing/export of hundreds of parasite proteins. This may be a novel
strategy to combat parasite growth.
Results
PfTrx-2 expression, purification, antibody generation and
localization. Recombinant PfTrx-2 was very prone to precipi-
tation, and to reduce protein precipitation buffers were maintained
in 5 mM DTT while precipitates were pelleted out. The remaining
PfTrx-2insupernatantswasfoundtobefullyactive(Fig.1a)andwas
used for all biochemical and crystallization experiments. PfTrx-2 was
previously shown to be localized to the parasite mitochondrion using
GFP-PfTrx2 constructs
28. More recently, it was shown to be resident
in the parasite PVM and to an unknown parasite organelle
13,14.W e
generated antibodies against recombinant PfTrx-2 in rabbit to verify
localization of PfTrx-2 at different stages of parasite life cycle. We
confirm that PfTrx-2 is localized to the PVM (only) in different
asexual stages of Plasmodium (Fig. 2, supplementary movies 1,
2a n d3 ) .
Crystallization and crystal structure of PfTrx-2. Hexagonal-
shaped crystals were obtained using hanging drop vapor diffusion
method by incubating 1 ml of protein with 1 ml of buffer containing
2.2 M ammonium sulfate and 0.125 mM bis-tris (pH 5.5) at 20uC
over a period of ,5 days. The crystals belong to space group P3221
with two monomers of PfTrx-2 in the asymmetric unit and a
solvent content of ,71%. Attempts to solve the crystal structure
of PfTrx-2 by molecular replacement failed and PfTrx-2 was
solved by MIRAS techniques using native data along with plati-
num and mercury derivatives (Table 1, PDB ID 3UL3).O v e r a l l
structure of PfTrx-2 consists of four b strands (b1, b2, b3a n d
b4), three a helices (a1, a2a n da3) and an extended N-terminus
named L1 (residues 56–71) (Fig. 1b). In PfTrx-2 crystal structure,
25 residues (amino acid numbers 29–53) are disordered as no
clear electron density was obvious for them in either 2Fo-Fc or
Fo-Fc maps. No clear side chain density was observed for residues
from 54 to 68. The overall fold of PfTrx-2 is similar to those of
other thioredoxins except for the L1 segment. This extended coil
region in PfTrx-2 contacts the other monomer of PfTrx-2 in
asymmetric unit (Fig. 3a and 3b). The resulting monomer -
monomer contacts are not extensive (total surface area per
PfTrx-2 is ,5100 A ˚ 2; buried surface area per PfTrx-2 ,134.5
Figure 1 | PfTrx-2activityandstructure. (a)InsulinreductionassayofPfTrx-2activity.(b)AcartoonrepresentationofthecrystalstructureofPfTrx-2.
ahelicesarecoloredmagenta,bsheetsarecoloredyellowwhilebturnsandloopregionsarecoloredblue.Activesitecystinesareshownassticksattheend
ofa1helix.(c)AdomaindiagramofPfTrx-2representingthestructuralelementsidentifiedinthecrystalstructure.Thecolorcodingisthesameasin(b).
Residues 1–24 forms the signal sequence region, amino-acids 24–53 are disordered while residues 54–157 form the thioredoxin fold.
www.nature.com/scientificreports
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only partially by interactions with the second PfTrx-2 in the crystal
asymmetric unit (Fig. 3a and 3b). The active site residues of PfTrx-2
(WCQAC) are present at beginning of a1 helix (Fig. 3c).B o t h
molecules of PfTrx-2 are in reduced form with distances between
S
c atoms of Cys 82 and Cys 85 of ,3.7 A ˚ and 3.9 A ˚ for A and B
chains respectively (Fig. 3c and 3d). Typical distances between
sulfurs in disulfide bridges are in , 2A ˚ range, and a distance of
,3.6 A ˚ represents the minimum distance when a disulfide bridge is
absent. We therefore conclude that PfTrx-2 structure is in a reduced
state; despite repeated efforts we were unable to obtain crystals of
oxidized PfTrx-2. As expected, PfTrx-2 Cys 85 (pKa ,11) is buried
inside the protein while Cys 82 (pKa ,8) is exposed in the loop
region at a1 helix terminus. Cys 82 is the active cysteine that likely
makes the first nucleophilic attack on substrate disulfides leading to
formation intermolecular disulfide bond. This link between PfTrx-2
and its substrate is then likely attacked by Cys 85 which acts as the
nucleophile and releases the substrate. The active site Trp 81 is
stabilized by an intramolecular hydrogen bond with Asp 111
(Fig. 3d) and is solvent exposed.
Comparison with human mitochondrial thioredoxin. Reduced
form of human mitochondrial thioredoxin (PDB code 1UVZ) was
superimposed on PfTrx-2 using Chimera
29. PfTrx-2 shares ,23%
sequenceidentitywithHuTrx-2(mitochondrialthioredoxin)overits
entire length (Fig. 4a). Active site region is only partially conserved
(PfTrx-2: WCQAC; Hu-Trx-2: WCGPC) between the two, however
their tertiary structures are reasonably conserved (Fig. 4b). The
greatest deviation is observed over the N-terminal parts of the
structures where the first b sheet and first a helix of the human
enzyme are absent in case of PfTrx-2 (Fig. 4a). Instead, the N-
terminus of PfTrx-2 forms an extended (L1) coiled region
(Fig. 4a). When the active site regions of HuTrx-2 and PfTrx-2
were superimposed, we noted several structural variations. Gly 32
andPro33ofHuTrx-2arereplacedbyGln83andAla84inPfTrx-2.
Similarly,thesmallerVal45inhelixa2(a1inPfTrx-2)isreplacedby
Gln96inPfTrx-2,whoselargersidechainwouldstericallyclashwith
residues in first b sheet of HuTrx-2. In HuTrx-2, Glu42 and Thr2
interacttostabilizethefirstbsheetwhilethisisnotpossibleinPfTrx-
2. Comparision of human and parasite Trx-2 suggests that the first a
helix and b sheet in PfTrx-2 are displaced relative to HuTrx-2. This
distortionintheformerresultsin,18sand,80uvariationrelative
to HuTrx-2, exposes PfTrx-2 b strands beneath (Fig. 4a) and creates
a groove on the surface of PfTrx-2 (Fig. 4c).
Surface features of PfTrx-2. The electrostatic surface of PfTrx-2
seems positively charged in contrast to the other thioredoxins
(including HuTrx-2) that display negatively charged surfaces
(Fig. 5a and 5b). Binding of HuTrx-2 with electron acceptor
proteins is predicted to involve an acidic cavity near the active site
on HuTrx-2 surface – complemented by a basic protuberance due to
Lys49 of electron acceptor protein hPDX5
30,31–34. Residues in this
region are conserved in both human and Plasmodium Trx-2
(highlighted by red colored box in Fig. 4b) suggesting retention of
binding interfaces for some substrate proteins. However, the L1
region of PfTrx-2 is altogether different from other thioredoxins
both electostatically and structurally. A positively charged groove
is observed at the L1 region, formed by residues from L1 and from
four b strands (Fig. 4c). One side of this basic groove is formed by
a2 helix while the other is formed by L1 segment. Sequence analysis
of other PTEX components shows that two of them viz. PTEX 150
and EXP2 have acidic repeats. Therefore, charge complimentarity
between noted regions of PfTrx-2 and PTEX150/EXP2 could result
in their engagement with each other (Fig. 4c).
PfTrx-2 Activity inhibition by Aurothiomalate (ATM). ATM is
known to inhibit the thioredoxin system
35,36. Although, ATM was
tested for treatment of malaria
37,38, its mechanism of action is only
partially explained by stimulation of eryptosis. Moreover, oxidative
stressisknowntostimulateeryptosis
39.Therefore,eryptosismightbe
an indirect outcome of the action of ATM on thioredoxin system
leading to oxidative stress. To investigate this hypothesis, we tested
Figure 2 | Visible and fluorescence images of 3D7 P. falciparum parasite immunostained with PfTrx-2 antibodies.
www.nature.com/scientificreports
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ATM was able to inhibit the PfTrx-2 activity in a dose dependent
manner with an IC50 of ,20 mm. (Fig. 6a).
In-silico docking of drug-like libraries on PfTrx-2 crystal
structure. PfTrx-2 structure shows many unique features which
seem useful for selective targeting by drug like compounds. Three
regions on the protein surface were selectively targeted - Region 1,
Region 2 and Region 3 (Fig. 7a). Region 1 is the area on the protein
surface surrounding the active site. We selected this region as
residues in the active site are only partially conserved between
humans and Plasmodium (Pf: CQAC, Hu: CGPC). Region 2 is the
extendedL1regionuniquetoPfTrx-2,whileregion3istheregionon
one side of the L1 region (Fig. 7a). Interestingly, top hits docked
mostly to L1 (region 2) with a few compounds docking to regions
1 and 3. We tested top 29 inhibitors which together docked to all
threeregionsonPfTrx-2surfaceinparasiteviabilityassays(Fig.6b).
Of the 29, four inhibitors were able to inhibit parasite growth in
micromolar ranges and gave reasonable values for IC50 (Fig. 6c).
Intriguingly, the most potent inhibitors from our set docked to the
L1regionofPfTrx-2(Fig.7c,7d,7eand7f).Inhibitor#20,themost
effective of those tested, partially shares binding site on PfTrx-2
surface with inhibitor #18 (Fig. 6b, 7a, 7b and 7c and 7e).
Inhibitor #28 docked to region 3 of PfTrx-2 (Fig. 7a and 7f), while
inhibitor #19 docked within the L1 region but distal from where
inhibitor 18 and 20 docked (Fig. 7a and 7d). Despite having
different skeletal types (the SPECS diversity set library was used),
these inhibitors seem to make similar interactions with residues on
surface of PfTrx-2. They therefore can serve as chemical starting
points for development of more specific and potent Trx2 inhibitors.
Discussion
Malaria parasites have evolved clever strategies for survival in mul-
tiple hosts. One such facet to malaria parasites is their ability to
extensively remodel host cells by exporting numerous parasite pro-
teins
15–18. PfTrx-2 is a component of the translocon of exported
proteins (PTEX), located on the parasite PVM where it purportedly
helps in protein folding/unfolding before substrate secretion. We
recombinantly expressed PfTrx-2 in E. coli and purified the protein
to homogeneity by conventional chromatographic techniques.
Protein activity was tested by an insulin reduction assay which sug-
gested enzymatically competent PfTrx-2 (Fig. 1a). In agreement
withearlierstudies,weconfirmedPVMlocalizationofPfTrx-2using
polyclonal antibodies specifically generated against recombinant
PfTrx-2 (Fig. 2). We could not confirm localization of PfTrx-2 to
any organelle of unknown identity inside the parasite as has been
reported earlier
13. Confocal imagery-based movies which show dis-
tinct localization of PfTrx-2 in the erythrocytic stages accompany
this manuscript (supplementary data).
Table 1 | X-Ray Data Processing, Structure Solution and Refinement Statistics Values in the parentheses are for the highest resolution shell.
Native Pt-Derivative Hg-Derivative
Data collection
Wavelength (A ˚) 1.07 1.07 1.07
Space group P32 21 P32 21 P32 21
Cell dimensions
a, b, c (A ˚) 86.61,86.61, 90.86 86.71,86.71, 90.14 87.05,87.05, 90.9
a, b, c 90, 90, 120 90, 90, 120 90, 90, 120
Resolution (A ˚) 10022.9 (3.0022.90) 50.0 2 3.5 (3.6323.50) 10023.2 (3.3123.20)
Rmerge 0.040(0.36) 0.083(0.569) 0.064(0.463)
I/s(I) 29.23(2.97) 50.89(5.0) 66.05(6.87)
Completeness (%) 98.2(99.1) 100(100) 99.9(100)
Redundancy 3.7(3.7) 14.4(14.9) 21.6(20.6)
Unique reflections 8947(877) 5222(511) 6929(672)
AutoSol
Bijivoet pairs 4358 5877
Mean anomalous signal
(,DF./,F).
0.0661 0.0388
SKEW 0.06 0.06
CORR_RMS 0.89 0.89
Bayesian CC 37.8 1/2 33.3 37.8 1/2 33.3
FOM 0.53 0.53
Sites used for phasing 3 4
Refined sites 34
AutoBulid
Residues built 178
Side chains placed 27
Rwork/Rfree 0.34/0.41
Model Map CC 0.71
Refinement
Resolution (A ˚) 39.26 2 2.90
No. reflections 8635
Rwork/Rfree 0.25/0.29
Number of atoms
Protein 1599
Water 33
Rmsd
Bond 0.02
Angle 1.68
B-factors
Protein 90.89
Water 58.73
www.nature.com/scientificreports
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in rat
36 and is used for the treatment of rheumatoid arthritis and
cancer
37. Interestingly, aurothiomalate also reduces Plasmodium
parasitemia both in vitro and in infected mice
38. However, the mech-
anism of anti-parasitic action for aurothiomalate could only be par-
tiallyexplained - entailing stimulation of eryptosis in infected RBCs
38.
Figure 4 | Comparision ofhuman and P.falciparum thioredoxin structures. (a)A structural superposition ofPftrx-2 (green) andHuTrx-2 (magenta).
L1regionisdisplaced by,18sand,80 degreesinPfTrx-2. (b)Astructure basedsequencealignment ofPfTrx-2andHuTrx-2. (c)Electrostatic surface
representation of PfTrx-2. A basic groove (marked by black arrow) is evident on the surface of PfTrx-2 where acidic regions of PTEX proteins can dock.
Figure 3 | Two molecules of PfTrx-2 in the crystallographic asymmetric unit. (a) A surface representation of PfTrx-2. (b) A cartoon representation
showing L1 regions of the two PfTrx-2 contacting each other. (c) Active site of PfTrx-2 showing two cysteines in a reduced state and (d) Trp 81 interacts
with the Asp 111 through a hydrogen bond.
www.nature.com/scientificreports
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dose dependent manner with an IC50 of ,20 mM (Fig. 6a).T h e
growth inhibitory effects of aurothiomalate might therefore be due
to blockage of protein secretion via the translocon where PfTrx-2
resides. Besides three thioredoxins and two thioredoxin-like proteins,
Plasmodium falciparum additionally encodes a thioredoxin reductase
Figure 5 | Comparison of surface electrostatics of (a) PfTrx-2 and (b) HuTrx-2. Each view is rotated by 180 degrees with respect to the previous view.
Figure 6 | PfTrx-2 inhibition assays. (a) Aurothiomalate inhibition assay. (b) Parasite growth inhibition assay (PIA) performed using 100 mMo f
different inhibitors. (c) PIA performed with four best inhibitors selected from (b) using a concentration range from 0.001 mM to 10000 mM.
www.nature.com/scientificreports
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drion of the Plasmodium parasites
13. One or several of these parasite
proteins could therefore be the target of aurothiomalate action.
Structural analysis of PfTrx-2 highlights unique features in the
Plasmodium enzyme when compared to its human counterpart
(Fig. 1b). The N-terminal a helix and b strand in HuTrx-2 are
replaced by an extended coil (L1 region) in PfTrx-2 structure. L1
is stabilized by interactions with another PfTrx-2 protomer in the
crystal asymmetric unit. This L1 region of PfTrx-2 is largely basic in
nature, and could potentially form interaction interfaces for the
numerous acidic regions in PTEX150 and EXP2 (Fig. 4c). The strik-
inglydifferentelectrostaticsurfacepropertiesofPfTrx-2andHuTrx-
2 suggest different modes of interaction, with possibly different pro-
tein partners (Fig. 5). Opposite locations for PfTrx-2 active site and
its L1 region suggests that the spatial segregation may be biologically
relevant. For example, one outcome of distal locations of PfTrx2
active site and L1 region may be to allow simultaneous engagement
of PfTrx2 with PTEX components on one side and substrates on the
other side. This unique architectural feature therefore presents
opportunities for targeting PfTrx-2 with small molecular inhibitors
directed against one or both sites. Our crystallographic analysis
therefore supports targeting PfTrx-2 for structure guided drug
design. Interestingly, our in silico docking studies with drug-like
libraries show that most of the top docking poses localize within
the L1 region of PfTrx-2 (region 2 in Fig. 6b, Fig. 7a). In summary,
our structural-functional and inhibitor discovery data together pro-
vide a platform for development of more potent PfTrx-2 inhibitors
that can impede protein export from malaria parasites by interfering
with the interaction interfaces of PfTrx-2.
Methods
Molecularcloning,ExpressionandPurification.PfTrx-2gene containsapredicted
ER signal sequence at the N-terminus. Gene construct of PfTrx-2, without its signal
sequence from amino acids 28–157, was designed for optimal expression in E. coli.
The construct was sub-cloned in pGEX4T1 vector with BamH1 and Sal1 restriction
sites and protein was expressed as a GST fusion. For overproduction of the fused
protein,EscherhichiacoliLemo21DE3competentcellswerefreshlytransformed,and
a single colony was grown in 10 ml of LB media containing 100 mg/ml ampicillin.
After 12 hours of growth, this seed culture was used to inoculate 1 liter of LB media
that was grown for 3.5 hours at 37uC. Protein expression was induced by adding
0.25 mM isopropyl b-D-thioglactopyranoside, and the culture was grown for
20 hours post-induction at 16uC. Cells were harvested by centrifugation at 5000 X g
for 15 minutes. The resulting bacterial pellet was suspended in a buffer containing
1XPBS, 5 mM DTT and protease inhibitor cocktail (Roche). Cells were lysed by
sonication and cleared by centrifugation at 20,000 X g for 45 minutes. The cleared
supernatant was applied to 5 ml GST FF column (GE Biosciences). The GST-Trx2
fusion protein was purified by elution with a buffer containing 1XPBS, 5 mM DTT
and 20 mM reduced glutathione on AKTA automated protein purifier (GE
Biosciences). The purified protein was desalted in 1X PBS containing 5 mM DTT
using a desalting column and the GST tag wasremoved by incubating with thrombin
protease in 1XPBS (GE Biosciences) at 20uC overnight. The cleaved protein was
concentrated by using 3 KDa cutoff centricon centrifugal device (Millipore) and
purified by gel filtration chromatography on S75 gel-filtration column (GE
Biosciences). Best fractions were checked by SDS-PAGE and those containing pure
PfTrx-2 werepooledand buffer-exchanged in20 mMTrispH8.0,20 mMNaCl and
10 mM DTT. The protein was concentrated to 5 mg/ml using a 3 KDa centricon
centrifugal device (Millipore) and stored at 280uC.
Immunofluorescence assays using confocal microscopy. Anti-PfTrx-2 antibodies
raised in a rabbit were used in immunofluorescence assays for localization of native
PfTrx-2 within malaria parasites.The assay was performed asdescribedearlier
40.C e l l s
were washed in PBS and fixed in solution using 4% paraformaldehyde and 0.0075%
glutaraldehyde in PBS for 25 minutes. After a PBS wash, cells were permeabilized by
using 0.1% Triton X-100 in PBS for 10 minutes. After another PBS wash, cells were
treated with0.1 mg/mlsodium borohydridein PBS for 10 minutes. Cells were washed
again with PBS, blocked in 3% BSA/PBS for 1 hour and incubated overnight with
protein-A column purified rabbit anti-protein IgG antibody (15250 dilution) at 4uC.
Cells were washed three times with PBS for 10 minutes each and incubated with
Alexaflour488–taggedanti-rabbitsecondaryantibodyfor1 houratroomtemperature
and allowed to settle onto coverslips coated with poly-L-lysine (100 mg/ml). Finally,
the coverslips were washed three times in PBS, mounted in antifade with DAPI
reagent (Invitrogen) and sealed. Confocal microscopy was performed on a Nikon
eclipse TE2000U microscope. Pre-immune sera were taken as negative controls.
Crystallization, Data Collection and Structure Determination. PfTrx-2 crystals
were obtained at 20uC by hanging drop vapor diffusion method using 1 mlo fP fT r x - 2
(5 mg/ml) and 1 ml of 0.125 M Bis-tris pH 5.5, 2.2 M ammonium sulfate and 5 mM
DTT. Single, hexagonal shaped crystals were added to a cryoprotectant solution
containing 0.125 mM Bis-tris pH 5.5, 3.0 M ammonium sulfate and 20% glycerol for
1 minute before flash freezing in cooled nitrogen gas at 100 K. For phasing, crystals
were soaked in 100 mM mercury (II) potassium iodide in cryoprotectant solution
Figure 7 | In-silico docking of inhibitors on PfTrx-2. (a) Three regions selected for docking analysis showing the 29 inhibitors selected for parasite growth
inhibition assay (PIA). (b) Molecular structure of top four inhibitors (Inhibitornumber 18, 19,20, and 28,respectively)(18) C18H16F3N3O(3,3-dimethyl-
6-(trifluoromethyl)-2,3,4,7-tetrahydro-1H-indolo[2,3-c]quinolin-1-one oxime) (19) C17H21N3O2 (3-benzyl-6-(cyclohexylamino)-2,4(1H,3H)-
pyrimidinedione)(20) C21H20N2 (10-azapentacyclo[11.6.3.0,2,11,.0,4,9,.0,14,19,]docosa-2(11),3,5,7,9,14,16,18-octaen-3-ylamine) and (28)
C18H13N5S (3-amino-5-anilino-4-(1H-benzimidazol-2-yl)thiophene-2-carbonitrile). (c)–(f) Docking of top four inhibitors from PIA on PfTrx-2 surface.
www.nature.com/scientificreports
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idobis(ethylenediamine) diplatinum (II) nitrate incryoprotectant solutionbefore flash
freezing. X-ray diffraction data were collected on a MARCCD detector at BM14 beam
lineofEuropeanSynchrotronRadiationFacilityatGrenoble,France.Pt(II)and Hg(II)
derivative datasets were collected along with native data in frozen conditions. The
diffraction images were processed and scaled with HKL2000 suite program
41.F o u rH g
and three Pt sites were found by AutoSol in Phenix and by SHELXD
42,43.P fT r x - 2
crystals are trigonal and belong to the space group P3221 (Table 1). The structure was
solved by MIRASprocedures using native and derivative datasets in PHENIX
42. Initial
model was build by AutoBuild in PHENIX, which was subsequently rebuilt manually
using COOT
44. Model refinement was performed using phenix.refine in PHENIX
42.
Activity assay and Inhibition of PfTrx-2 activity. Enzymatic activity of
recombinant PfTrx-2 was determined by insulin reduction assay
45. Briefly, 2.0 – 8.0
mgofrecombinantPfTrx-2wasusedin1 mlof0.1 Mpotassiumphosphate(pH7.0),
2 mM EDTA, 0.1% bovine insulin, and 1 mM DTT. The same buffer without DTT
was used as reference. Protein concentration was determined by using the Bio-Rad
protein assay kit with BSA as standard. Thioredoxin activity was measured at 25uC
anddefinedasthemaximalincreaserateofturbidityatO.D.at650 nmduetoinsulin
precipitation
45.ForinhibitionofPfTrx-2activity,varyingamountsofinhibitorswere
added in the reaction mixtures and decrease in turbidity at O.D. 650 nm due to
inhibition of insulin precipitation was measured.
In silico screening of PfTrx-2 inhibitors. Molecular docking and in silico screening
were carried using PfTrx-2 structure in docking program AutoDock vina
46 with a
SPECS‘‘Specsworlddiversity’’library.ThelibrarywaspreparedusingLigprepmodule
in Schrodinger software suite to ensure proper partial charges and protonation states.
Physiochemicalpropertieswerepredicted using QikpropmoduleinSchro ¨dinger suite.
For in silico screening, we applied 10 lead-like filters derived from Lipinski’s rule of
five: 1, QPlogPo/w , 4; 100 , molecular weight , 350; H donor , 5; H acceptor ,
10; rotatable bounds , 15; 25 , QPlogS . 21; 300 A ˚ , SASA . 1000 A ˚;0A ˚ ,
FOSA.750 A ˚;7A ˚ ,FISA.330 A ˚,F I S A. FOSA.After aninitial lead-likefiltering
process, 900 compounds were collated for screening. The top docking poses were
isolated from each output file for further analysis. Top ligands were selected based on
docking scores and H-bond interactions with residues in PfTrx-2.
ParasiteGrowthInhibitionAssays.Top inhibitorsselected viaaboveprocedurewere
tested on malaria parasite P. falciparum 3D7 strain. Parasites were synchronized using
sorbitol and starting with ring stages these parasites were cultured in 96 well plates at
1% parasitemia and 2% hematocrit. Initial screening of all top compounds was
performed by growing parasites at 100 mM inhibitor concentration. After 48 hours of
growth, parasitemia was measured by fluorescence assay as described earlier
47.B r i e f l y ,
culture was lysed by adding 100 ml of lysis buffer [Tris (20 mM, pH 7.5), EDTA
(5 mM), saponin (0.008%, w/v) and Triton X-100(0.08%, w/v)], SYBR green I was
added to each well (0.2 ml of SYBR Green in 1 ml of lysis buffer), and mixed until no
erythrocyte sediments were visible. After 1 hour incubation in dark at room
temperature, fluorescence was measured with multi-well plate reader (Victor3, Perkin
Elmer) at excitation and emission wavelength bands centered at 485 nm and 530 nm,
respectively. To access the effect of selected inhibitors, fluorescence readings were
compared and subtracted from fluorescence values at 100% parasite inhibition -
fluorescence value at 100 mM chloroquine was taken as 100% parasite growth
inhibition. We then calculated percentage parasitemia for each inhibitor. To further
validatetheanti-malarialactivityoftopcompoundsfromthisfirstscreen,experiments
were repeated with a broader range of inhibitor concentrations ranging from 1 nM to
1 mM. Each experiment was repeated three times and each value is average of four
measurements. These data were used to calculate IC50 values for each inhibitor.
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